RYTHMODAN

This brand name is authorized in Australia, Canada, France, Japan, Malta, New Zealand, South Africa, UK.

Active ingredients

The drug RYTHMODAN contains one active pharmaceutical ingredient (API):

1	Disopyramide UNII GFO928U8MQ - DISOPYRAMIDE
	Disopyramide is a myocardial depressant and has anti-cholinergic effects. It decreases membrane responsiveness, prolongs the effective refractory period (ERP) and slows automaticity in cells with augmented automaticity.
	Read more about Disopyramide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYTHMODAN Capsules	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
Rythmodan 100mg Capsules	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01BA03	Disopyramide	C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BA Antiarrhythmics, class Ia
Discover more medicines within C01BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2923W
CA	Health Products and Food Branch	02224801
FR	Base de données publique des médicaments	63063487, 69235837
GB	Medicines & Healthcare Products Regulatory Agency	158597, 34655
JP	医薬品医療機器総合機構	2129002M1060, 2129002M2139, 2129005F1129, 2129401A1070
MT	Medicines Authority	AA565/29302
NZ	Medicines and Medical Devices Safety Authority	1702
ZA	Health Products Regulatory Authority	E/6.2/163